Blocking effect for percutaneous HIV infection by exposure of semen collected after oral administration of Maraviroc

Research Project

Project/Area Number	24791143
Research Category	Grant-in-Aid for Young Scientists (B)
Allocation Type	Multi-year Fund
Research Field	Dermatology
Research Institution	University of Yamanashi
Principal Investigator	MATSUZAWA Takamitsu 山梨大学, 医学部附属病院, 医員 (40568028)
Project Period (FY)	2012-04-01 – 2014-03-31
Project Status	Completed (Fiscal Year 2013)
Budget Amount *help	¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000) Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2012: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	HIV感染予防法 / 国内研究
Research Abstract	In light of the absence of a prophylactic vaccine, therapeutic strategies that reduce sexual transmission of HIV are urgently needed. In this study, we evaluated whether exposure of semen collected after oral administration of Maraviroc (MVC), which is a orally available antagonist for CCR5 and has been clinically used for AIDS therapy, demonstrated potent blocking effect for HIV infection or not. We evaluated by using an ex vivo skin explant model. Even if volunteers were orally administrated MVC (600mg/day) for 1, 2, 3, or 14 days and then semen was collected, exposure of semen to epidermal sheets obtained from another volunteers had not significant blocking effect for HIV infection in epidermal LCs.